NCT05263284View on ClinicalTrials.gov

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

January 25, 2027

Study Completion Date

January 25, 2027

Conditions
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

8-Chloroadenosine

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER